小RNA
生物
癌症研究
细胞凋亡
肝细胞癌
血管生成
转移
上皮-间质转换
细胞生长
抗药性
癌症
生物信息学
基因
遗传学
生物化学
微生物学
作者
Masoumeh Hajizadeh,Farnaz Hajizadeh,Sevil Ghaffarei,Mohammad Amin Doustvandi,Khadijeh Hajizadeh,Shahriar Yaghoubi,Fateme Mohammadnejad,Nadia Allahyarzadeh Khiabani,Pegah Mousavi,Behzad Baradaran
出处
期刊:Gene
[Elsevier]
日期:2023-12-01
卷期号:888: 147803-147803
被引量:4
标识
DOI:10.1016/j.gene.2023.147803
摘要
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies with high invasive and metastatic capability. Although significant advances have been made in the treatment of HCC, the overall survival rate of patients is still low. It is essential to explore accurate biomarkers for early diagnosis and prognosis along with therapeutic procedures to increase the survival rate of these patients. Anticancer therapies can contribute to induce apoptosis for the elimination of cancerous cells. However, dysregulated apoptosis and proliferation signaling pathways lead to treatment resistance, a significant challenge in improving efficient therapies. MiRNAs, short non-coding RNAs, play crucial roles in the progression of HCC, which regulate gene expression through post-transcriptional inhibition and targeting mRNA degradation in cancers. Dysregulated expression of multiple miRNAs is associated with numerous biological processes, including cell proliferation, apoptosis, invasion and metastasis, epithelial-mesenchymal transition (EMT), angiogenesis, and drug resistance in HCC. This review summarizes the role and potential efficacy of miRNAs in promoting and inhibiting cell proliferation and apoptosis in HCC, as well as the role of miRNAs in therapy resistance in HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI